Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Gnanasakthy

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
JAMA Oncology|July 17, 2015
Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the PatientEthan Basch, Cindy Geoghegan, Stephen Joel Coons, et al.
Muscle & Nerve|February 14, 2016
Psychometric validation of a patient-reported measure of physical functioning in sporadic inclusion body myositisValerie Williams, Theresa Coles, Ari Gnanasakthy, et al.
NPJ Digital Medicine|April 3, 2026
Sensor-based digital health technologies to capture endpoints in recent clinical trials: a scoping reviewJulia Garcia, Margaret M Mordin, Bidur Banjara, et al.
The Journal of Dermatological Treatment|March 8, 2017
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumabBoni E Elewski, Lluís Puig, Margaret Mordin, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 25, 2021
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaAlexander Spira, Xiaolei Zhou, Lei Chen, et al.
Journal of the American Academy of Dermatology|January 15, 2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanerceptBruce Strober, Alice B Gottlieb, Bintu Sherif, et al.
Orphanet Journal of Rare Diseases|February 6, 2022
Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiencyPeter Kühnen, Martin Wabitsch, Julia von Schnurbein, et al.
European Journal of Haematology|December 28, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trialFredrik Schjesvold, Hartmut Goldschmidt, Vladimir Maisnar, et al.
International Journal of Dermatology|November 1, 2015
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasisBruce Strober, Yang Zhao, Mary Helen Tran, et al.
Orphanet Journal of Rare Diseases|January 16, 2023
Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial resultsElizabeth Forsythe, Robert M Haws, Jesús Argente, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
JAMA Oncology|July 17, 2015
Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the PatientEthan Basch, Cindy Geoghegan, Stephen Joel Coons, et al.
Muscle & Nerve|February 14, 2016
Psychometric validation of a patient-reported measure of physical functioning in sporadic inclusion body myositisValerie Williams, Theresa Coles, Ari Gnanasakthy, et al.
NPJ Digital Medicine|April 3, 2026
Sensor-based digital health technologies to capture endpoints in recent clinical trials: a scoping reviewJulia Garcia, Margaret M Mordin, Bidur Banjara, et al.
The Journal of Dermatological Treatment|March 8, 2017
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumabBoni E Elewski, Lluís Puig, Margaret Mordin, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 25, 2021
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaAlexander Spira, Xiaolei Zhou, Lei Chen, et al.
Journal of the American Academy of Dermatology|January 15, 2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanerceptBruce Strober, Alice B Gottlieb, Bintu Sherif, et al.
Orphanet Journal of Rare Diseases|February 6, 2022
Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiencyPeter Kühnen, Martin Wabitsch, Julia von Schnurbein, et al.
European Journal of Haematology|December 28, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trialFredrik Schjesvold, Hartmut Goldschmidt, Vladimir Maisnar, et al.
International Journal of Dermatology|November 1, 2015
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasisBruce Strober, Yang Zhao, Mary Helen Tran, et al.
Orphanet Journal of Rare Diseases|January 16, 2023
Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial resultsElizabeth Forsythe, Robert M Haws, Jesús Argente, et al.
Pageof 6